Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis

Table 5

The abilities of combination2 and CA19-9 in PC diagnosis.

Project	AUC (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Accuracy (95% CI)	Kappa (95% CI)
Combination2	0.974 (0.958–0.991)	0.890 (0.847–0.933)	0.906 (0.861–0.951)	0.886 (0.864–0.909)	0.769 (0.722–0.817)
CA19-9	0.821 (0.765–0.874)	0.791 (0.745–0.826)	0.826 (0.765–0.894)	0.813 (0.778–0.834)	0.673 (0.603–0.747)